BioXcel Therapeutics (BTAI) Common Equity (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Common Equity of -$105.5 million for Q1 2026, down 17.05% year-over-year from -$127.2 million in Q1 2025, and down 10.56% quarter-over-quarter from -$95.5 million in Q4 2025.
BioXcel Therapeutics (BTAI) Common Equity (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.
- In Q1 2026, Common Equity fell 17.05% year-over-year to -$105.5 million; the TTM figure through Mar 2026 stood at -$105.5 million (down 17.05% YoY), while the FY2025 annual figure was -$95.5 million, down 2.54% from the prior year.
- Common Equity for Q1 2026 stood at -$105.5 million, down from -$95.5 million in the prior quarter.
- The five-year high for Common Equity was $194.0 million in Q1 2022, with the low at -$107.7 million in Q2 2025.
- The 5-year median for Common Equity is -$72.4 million (2024), against an average of -$17.0 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity advanced 3.9% in 2022, then sank 1367.07% in 2024.
- BioXcel Therapeutics' Common Equity stood at $76.8 million in 2022, then plunged by 173.6% to -$56.5 million in 2023, then slumped by 64.76% to -$93.1 million in 2024, then declined by 2.54% to -$95.5 million in 2025, then retreated by 10.56% to -$105.5 million in 2026.
- Business Quant data shows BTAI's Common Equity at -$105.5 million in Q1 2026, -$95.5 million in Q4 2025, and -$88.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | -115.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -115.46 Mn |
| Mar 31, 2026 | -105.54 Mn |
| Dec 31, 2025 | -95.46 Mn |
| Sep 30, 2025 | -88.92 Mn |
| Jun 30, 2025 | -107.67 Mn |
| Mar 31, 2025 | -90.17 Mn |
| Dec 31, 2024 | -93.10 Mn |
| Sep 30, 2024 | -85.63 Mn |
| Jun 30, 2024 | -74.30 Mn |
| Mar 31, 2024 | -72.36 Mn |
| Dec 31, 2023 | -56.51 Mn |
| Sep 30, 2023 | -40.61 Mn |
| Jun 30, 2023 | 5.86 Mn |
| Mar 31, 2023 | 53.01 Mn |
| Dec 31, 2022 | 76.78 Mn |
| Sep 30, 2022 | 126.99 Mn |
| Jun 30, 2022 | 164.26 Mn |
| Mar 31, 2022 | 194.02 Mn |
| Dec 31, 2021 | 221.67 Mn |
| Sep 30, 2021 | 245.56 Mn |